First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Novartis AG (NVS): the developments shaping its investment case

    Follow the evidence affecting Novartis AG. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Novartis AG · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-01
    Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
    Channel: Successful Phase III trial for a novel drug in a significant market (MS) increases future revenue potential and strengthens pipeline. Reduces R&D risk.
    Bullish· 1-5y
    2026-09-01
    Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
    Channel: Successful Phase III trial for a novel drug in a significant market (MS) strengthens future revenue streams and pipeline value.
    Bullish· 1-5y
    2026-09-05 · 2 reports
    Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
    Channel: Direct R&D failure, loss of potential future revenue stream from a key pipeline asset.
    Bearish· 1-3m

    Event impact log

    16 events mapped to NVS since 2026-09-01. Evidence through 2026-09-24.

    DateEventChannelDirectionHorizonImpact
    2026-09-24Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026Potential competitive pressure or validation of the CAR T cell therapy approach in autoimmune diseases. Novartis is a leader in CAR T therapies.watch3-12m0.20
    2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthDirect revenue growth from increased adoption and market expansion of existing CAR-T therapies (Kymriah) in hematologic oncology.Bullish1-5y0.60
    2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyIncreased competition in the Spinal Muscular Atrophy (SMA) market, potential erosion of market share for Zolgensma.Bearish3-12m0.50
    2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMAIncreased competition in the Spinal Muscular Atrophy (SMA) market. Similar to Biogen, Novartis's SMA treatment may face altered market dynamics due to a new combination therapy option.mixed3-12m0.30
    2026-09-13FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA TherapyIncreased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies.mixed3-12m0.30
    2026-09-13FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyPotential competitive pressure or market expansion in the SMA treatment landscape.watch3-12m0.30
    2026-09-12FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMAIncreased competition in the SMA treatment market, potential for market share shift or pricing pressure.watch3-12m0.30
    2026-09-12FDA Approves Isembyld for Spinal Muscular AtrophyIncreased competition in the SMA treatment market, potential erosion of market share for existing gene therapies.Bearish1-3m0.40
    2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapyIncreased competition in the Spinal Muscular Atrophy (SMA) treatment market.Bearish1-3m0.40
    2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophyIncreased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies.mixed3-12m0.30
    2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointDirect R&D failure, loss of potential future revenue stream from a key pipeline asset.Bearish1-3m0.80
    2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MDirect pipeline failure, loss of future revenue potential from a key drug candidate.Bearish1-3m0.70
    2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary EndpointDirect R&D failure, loss of potential future revenue stream, increased R&D write-offs.Bearish1-3m0.80
    2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS TrialsDirect product pipeline success, potential for new revenue stream and market share gain in MS.Bullish1-5y0.80
    2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS TrialSuccessful Phase III trial for a novel drug in a significant market (MS) increases future revenue potential and strengthens pipeline. Reduces R&D risk.Bullish1-5y0.90
    2026-09-01Novartis Reports Positive Phase III Results for Remibrutinib in Multiple SclerosisSuccessful Phase III trial for a novel drug in a significant market (MS) strengthens future revenue streams and pipeline value.Bullish1-5y0.85

    Continue this research

    Build your Novartis AG investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the NVS entity page →

    Research Novartis AG · $399/mo